In 1960, the therapeutic indications for a mixture of an estrogen and a progestogen were extended to include contraception in the labeling approved by the Food and Drug Administration. Since then, the Council on Drugs has published various evaluations of individual oral contraceptive preparations and of these drugs as a group. In theJournal of The American Medical Association, Feb 27, 1967 (199:650-653), the Council on Drugs expressed the philosophy of the Council in the following statement from itsEvaluation of Oral Contraceptives: The development of the oral contraceptives, which readily control certain of the physiologic processes leading to conception, has broadened the meaning of the term therapeutics. For these pharmaceutic preparations are given to healthy people, and any possible hazards connected with their use, however remote, must be weighed against their expected benefits, perhaps more critically than has ever been the case before. This is often an uneasy